# Hemostemix Presents ACP-01 Limb Preservation Clinical Evidence at Innovations in Wound Healing Conference

> news · REPORTED · 2025-12-03

Hemostemix highlighted its four published clinical studies validating ACP-01's ability to regenerate microvascular circulation in chronic limb-threatening ischemia at the Innovations in Wound Healing 2025 conference in Key West, positioning itself as a regenerative medicine leader in limb preservation where standard of care has remained largely unchanged for decades.

About Hemostemix: Hemostemix is a regenerative medicine company developing ACP-01, an autologous cell therapy intended to regenerate microvascular circulation in patients with chronic limb-threatening ischemia to prevent amputation.

- Company: Hemostemix
- Sector: therapeutics
- Primary source: https://www.biospace.com/press-releases/hemostemix-featured-at-innovations-in-wound-healing-2025-key-west-december-11-14

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.